Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
—
—
—
—
—
—
1 Year
Score—
Net Growth—
Net Trend—
Net Income Consistency—
Rev Growth—
Rev Trend—
Revenue Consistency—
5 Years
—
—
25%
—
—
Never
—
5 Years
Score—
Net Growth—
Net Trend25%
Net Income Consistency—
Rev Growth—
Rev TrendNever
Revenue Consistency—
China SXT Pharmaceuticals Inc fundamental performance
Across China SXT Pharmaceuticals Inc's full reported history, from 2019 to 2026, revenue declined from $ 7M to $ 1M and net income went from $ 1M to -$ 6M. Revenue increased in 0% of the years measured; net income in 29%.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 3.30 | — |
1 Year2025-08-12 | $ 234.00 | -98.59% |
5 Years2021-08-12 | $ 4.65K | -99.93% |
All Time2019-01-04 | $ 86.1K | -100.00% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2019-01-04 |
|---|---|---|---|---|
| Price | $ 3.30 | $ 234.00 | $ 4.65K | $ 86.1K |
| Return | — | -98.59% | -99.93% | -100.00% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2027 | $ 28M | ||
| 2026 | $ 1M | -$ 6M | $ 28M |
| 2025 | $ 1M | -$ 3M | $ 18M |
| 2024 | $ 1M | -$ 3M | $ 12M |
| 2023 | $ 1M | -$ 5M | $ 17M |
| 2022 | $ 2M | -$ 5M | $ 15M |
| 2021 | $ 4M | -$ 2M | $ 13M |
| 2020 | $ 5M | -$ 10M | $ 7M |
| IPO2019 | $ 7M | $ 1M | $ 9M |
Explore beyond SXTC
You're looking at China SXT Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
